Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory CLL and low-grade B-cell NHL
NCT02332980Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2015
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), small lymphocytic lymphoma (SLL), Richter syndrome (RS), sponsored by Mayo Clinic. Started Feb 2015; status: completed.
02
Drugs
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)small lymphocytic lymphoma (SLL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT02332980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332980.